https://www.selleckchem.com/pr....oducts/cilofexor-gs-
Folate receptor alpha (FRα) is overexpressed in 80% of epithelial ovarian cancer (EOC). Accordingly, folate is attracting attention as a targeting ligand for EOC. For EOC patients, paclitaxel (PTX) is generally used as first-line chemotherapeutic agent in combination with platinum-based drugs. Cyclodextrin (CyD) is a potential new formulation vehicle for PTX that could replace Cremophor-EL, a traditional formulation vehicle that causes significant side effects including neutropenia. Recently, folate-appended β-CyD (Fol-c1
Aimer
Commentaire
Partagez
